Ferrous Sulfate
drugOn this page
Also known as CopperasFeosolFeospanFer-in-solFero-gradumetFerr sulfdriedFerrogradFerrosi sulfasFerrous ii sulfate heptahydrateFerrous sulfate (1:1)Ferrous sulfate anhydrousFerrous sulfate component of folvronFerrous sulfate heptahydrateFerrous sulfate hydrateanhydrousexsiccatedFerrous sulphateFerrous sulphate (1:1)
Summary
Ferrous Sulfate (CHEMBL1200830) is an approved small molecule (ATC B03AA07); indicated across 7 conditions including anemia and iron deficiency anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B03AA07
- Indications: 7 conditions
- Clinical trials: 134
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200830 |
| Name | Ferrous Sulfate |
| Type | Small molecule |
| Max phase | 4 |
| ATC | B03AA07 |
Also known as: Copperas, Feosol, Feospan, Fer-in-sol, Fero-gradumet, Ferr sulf, dried, Ferrograd, Ferrosi sulfas, Ferrous ii sulfate heptahydrate, Ferrous sulfate, Ferrous sulfate (1:1)
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| iron deficiency anemia | 3 | MONDO:0001356 | HP:0001891 |
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
| fibromyalgia | 3 | MONDO:0005546 | EFO:0005687 |
| hip fracture | 3 | MONDO:0005327 | EFO:0003964 |
| heavy metal poisoning | 2 | MONDO:0023305 | EFO:1001518 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 134.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 58 |
| PHASE4 | 28 |
| PHASE3 | 26 |
| PHASE2 | 13 |
| PHASE2/PHASE3 | 3 |
| EARLY_PHASE1 | 3 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03991169 | PHASE4 | RECRUITING | Oral Iron in Children With Chronic Kidney Disease |
| NCT04278651 | PHASE4 | RECRUITING | Early Antenatal Support for Iron Deficiency Anemia |
| NCT06550362 | PHASE4 | NOT_YET_RECRUITING | Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA |
| NCT07053475 | PHASE4 | RECRUITING | IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches |
| NCT07414199 | PHASE4 | NOT_YET_RECRUITING | The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department |
| NCT07605676 | PHASE4 | RECRUITING | Acupoint TENS vs Resistance Training for Iron Deficiency Anemia |
| NCT00224042 | PHASE4 | COMPLETED | Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents |
| NCT00224055 | PHASE4 | COMPLETED | Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients |
| NCT00224068 | PHASE4 | COMPLETED | Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy |
| NCT00689793 | PHASE4 | COMPLETED | Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors |
| NCT00830037 | PHASE4 | TERMINATED | A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease |
| NCT01444261 | PHASE4 | COMPLETED | Prevention of Iron Deficiency in Breastfed Infants |
| NCT01701310 | PHASE4 | COMPLETED | IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia |
| NCT01991314 | PHASE4 | COMPLETED | Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate |
| NCT02086968 | PHASE4 | COMPLETED | Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass |
| NCT02487719 | PHASE4 | UNKNOWN | Different Iron Supplements for Prevention of Anemia in Pregnancy |
| NCT02774057 | PHASE4 | UNKNOWN | Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD |
| NCT02825719 | PHASE4 | TERMINATED | Ulipristal Use in Chinese Population |
| NCT03524651 | PHASE4 | COMPLETED | Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia |
| NCT04017598 | PHASE4 | COMPLETED | Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia |
| NCT04205266 | PHASE4 | UNKNOWN | IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding |
| NCT04267653 | PHASE4 | COMPLETED | Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia |
| NCT04435574 | PHASE4 | COMPLETED | Lactoferrin for Treatment of Iron Deficiency Anemia. |
| NCT04594070 | PHASE4 | TERMINATED | Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy |
| NCT04608539 | PHASE4 | COMPLETED | A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery |
| NCT04610827 | PHASE4 | TERMINATED | Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder |
| NCT05007899 | PHASE4 | COMPLETED | Alternate Day Versus Daily Oral Iron Therapy in Adolescents |
| NCT05047211 | PHASE4 | COMPLETED | Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia |
| NCT04268849 | PHASE3 | RECRUITING | Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient |
| NCT05462704 | PHASE3 | RECRUITING | Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy |
| NCT06884280 | PHASE3 | RECRUITING | Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study |
| NCT00236977 | PHASE3 | COMPLETED | Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia |
| NCT00317239 | PHASE3 | COMPLETED | VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease |
| NCT00354484 | PHASE3 | COMPLETED | Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients |
| NCT00364104 | PHASE3 | COMPLETED | Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children |
| NCT00395993 | PHASE3 | COMPLETED | Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding |
| NCT00661999 | PHASE3 | COMPLETED | Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer |
| NCT00919230 | PHASE3 | COMPLETED | Randomised Trial Comparing Iron Supplementation Versus Placebo in the Treatment of Anaemia After Hip Fracture |
| NCT00929409 | PHASE2/PHASE3 | TERMINATED | Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia |
| NCT00982007 | PHASE3 | COMPLETED | Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anemia, iron deficiency anemia, heart failure, fibromyalgia, hip fracture